Cargando…
Mortality in Hemodialysis Patients with COVID-19, the Effect of Paricalcitol or Calcimimetics
Background. In COVID-19 patients, low serum vitamin D (VD) levels have been associated with severe acute respiratory failure and poor prognosis. In regular hemodialysis (HD) patients, there is VD deficiency and markedly reduced calcitriol levels, which may predispose them to worse outcomes of COVID-...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8401800/ https://www.ncbi.nlm.nih.gov/pubmed/34444716 http://dx.doi.org/10.3390/nu13082559 |
_version_ | 1783745637001461760 |
---|---|
author | Arenas Jimenez, María Dolores González-Parra, Emilio Riera, Marta Rincón Bello, Abraham López-Herradón, Ana Cao, Higini Hurtado, Sara Collado, Silvia Ribera, Laura Barbosa, Francesc Dapena, Fabiola Torregrosa, Vicent Broseta, José-Jesús Soto Montañez, Carlos Navarro-González, Juan F. Ramos, Rosa Bover, Jordi Nogués-Solan, Xavier Crespo, Marta Dusso, Adriana S. Pascual, Julio |
author_facet | Arenas Jimenez, María Dolores González-Parra, Emilio Riera, Marta Rincón Bello, Abraham López-Herradón, Ana Cao, Higini Hurtado, Sara Collado, Silvia Ribera, Laura Barbosa, Francesc Dapena, Fabiola Torregrosa, Vicent Broseta, José-Jesús Soto Montañez, Carlos Navarro-González, Juan F. Ramos, Rosa Bover, Jordi Nogués-Solan, Xavier Crespo, Marta Dusso, Adriana S. Pascual, Julio |
author_sort | Arenas Jimenez, María Dolores |
collection | PubMed |
description | Background. In COVID-19 patients, low serum vitamin D (VD) levels have been associated with severe acute respiratory failure and poor prognosis. In regular hemodialysis (HD) patients, there is VD deficiency and markedly reduced calcitriol levels, which may predispose them to worse outcomes of COVID-19 infection. Some hemodialysis patients receive treatment with drugs for secondary hyperparathyroidism, which have well known pleiotropic effects beyond mineral metabolism. The aim of this study was to evaluate the impact of VD status and the administration of active vitamin D medications, used to treat secondary hyperparathyroidism, on survival in a cohort of COVID-19 positive HD patients. Methods. A cross-sectional retrospective observational study was conducted from 12 March to 21 May 2020 in 288 HD patients with positive PCR for SARS-CoV2. Patients were from 52 different centers in Spain. Results. The percent of HD patients with COVID-19 was 6.1% (288 out of 4743). Mortality rate was 28.4% (81/285). Three patients were lost to follow-up. Serum 25(OH)D (calcidiol) level was 17.1 [10.6–27.5] ng/mL and was not significantly associated to mortality (OR 0.99 (0.97–1.01), p = 0.4). Patients receiving active vitamin D medications (16/94 (17%) vs. 65/191(34%), p = 0.003), including calcimimetics (4/49 (8.2%) vs. 77/236 (32.6%), p = 0.001), paricalcitol or calcimimetics (19/117 (16.2%) vs. 62/168 (36.9%); p < 0.001), and also those on both paricalcitol and calcimimetics, to treat secondary hyperparathyroidism (SHPTH) (1/26 (3.8%) vs. 80/259 (30.9%), p < 0.001) showed a lower mortality rate than patients receiving no treatment with either drug. Multivariate Cox regression analysis confirmed this increased survival. Conclusions. Our findings suggest that the use of paricalcitol, calcimimetics or the combination of both, seem to be associated with the improvement of survival in HD patients with COVID-19. No correlation was found between serum VD levels and prognosis or outcomes in HD patients with COVID-19. Prospective studies and clinical trials are needed to support these findings. |
format | Online Article Text |
id | pubmed-8401800 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84018002021-08-29 Mortality in Hemodialysis Patients with COVID-19, the Effect of Paricalcitol or Calcimimetics Arenas Jimenez, María Dolores González-Parra, Emilio Riera, Marta Rincón Bello, Abraham López-Herradón, Ana Cao, Higini Hurtado, Sara Collado, Silvia Ribera, Laura Barbosa, Francesc Dapena, Fabiola Torregrosa, Vicent Broseta, José-Jesús Soto Montañez, Carlos Navarro-González, Juan F. Ramos, Rosa Bover, Jordi Nogués-Solan, Xavier Crespo, Marta Dusso, Adriana S. Pascual, Julio Nutrients Article Background. In COVID-19 patients, low serum vitamin D (VD) levels have been associated with severe acute respiratory failure and poor prognosis. In regular hemodialysis (HD) patients, there is VD deficiency and markedly reduced calcitriol levels, which may predispose them to worse outcomes of COVID-19 infection. Some hemodialysis patients receive treatment with drugs for secondary hyperparathyroidism, which have well known pleiotropic effects beyond mineral metabolism. The aim of this study was to evaluate the impact of VD status and the administration of active vitamin D medications, used to treat secondary hyperparathyroidism, on survival in a cohort of COVID-19 positive HD patients. Methods. A cross-sectional retrospective observational study was conducted from 12 March to 21 May 2020 in 288 HD patients with positive PCR for SARS-CoV2. Patients were from 52 different centers in Spain. Results. The percent of HD patients with COVID-19 was 6.1% (288 out of 4743). Mortality rate was 28.4% (81/285). Three patients were lost to follow-up. Serum 25(OH)D (calcidiol) level was 17.1 [10.6–27.5] ng/mL and was not significantly associated to mortality (OR 0.99 (0.97–1.01), p = 0.4). Patients receiving active vitamin D medications (16/94 (17%) vs. 65/191(34%), p = 0.003), including calcimimetics (4/49 (8.2%) vs. 77/236 (32.6%), p = 0.001), paricalcitol or calcimimetics (19/117 (16.2%) vs. 62/168 (36.9%); p < 0.001), and also those on both paricalcitol and calcimimetics, to treat secondary hyperparathyroidism (SHPTH) (1/26 (3.8%) vs. 80/259 (30.9%), p < 0.001) showed a lower mortality rate than patients receiving no treatment with either drug. Multivariate Cox regression analysis confirmed this increased survival. Conclusions. Our findings suggest that the use of paricalcitol, calcimimetics or the combination of both, seem to be associated with the improvement of survival in HD patients with COVID-19. No correlation was found between serum VD levels and prognosis or outcomes in HD patients with COVID-19. Prospective studies and clinical trials are needed to support these findings. MDPI 2021-07-26 /pmc/articles/PMC8401800/ /pubmed/34444716 http://dx.doi.org/10.3390/nu13082559 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Arenas Jimenez, María Dolores González-Parra, Emilio Riera, Marta Rincón Bello, Abraham López-Herradón, Ana Cao, Higini Hurtado, Sara Collado, Silvia Ribera, Laura Barbosa, Francesc Dapena, Fabiola Torregrosa, Vicent Broseta, José-Jesús Soto Montañez, Carlos Navarro-González, Juan F. Ramos, Rosa Bover, Jordi Nogués-Solan, Xavier Crespo, Marta Dusso, Adriana S. Pascual, Julio Mortality in Hemodialysis Patients with COVID-19, the Effect of Paricalcitol or Calcimimetics |
title | Mortality in Hemodialysis Patients with COVID-19, the Effect of Paricalcitol or Calcimimetics |
title_full | Mortality in Hemodialysis Patients with COVID-19, the Effect of Paricalcitol or Calcimimetics |
title_fullStr | Mortality in Hemodialysis Patients with COVID-19, the Effect of Paricalcitol or Calcimimetics |
title_full_unstemmed | Mortality in Hemodialysis Patients with COVID-19, the Effect of Paricalcitol or Calcimimetics |
title_short | Mortality in Hemodialysis Patients with COVID-19, the Effect of Paricalcitol or Calcimimetics |
title_sort | mortality in hemodialysis patients with covid-19, the effect of paricalcitol or calcimimetics |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8401800/ https://www.ncbi.nlm.nih.gov/pubmed/34444716 http://dx.doi.org/10.3390/nu13082559 |
work_keys_str_mv | AT arenasjimenezmariadolores mortalityinhemodialysispatientswithcovid19theeffectofparicalcitolorcalcimimetics AT gonzalezparraemilio mortalityinhemodialysispatientswithcovid19theeffectofparicalcitolorcalcimimetics AT rieramarta mortalityinhemodialysispatientswithcovid19theeffectofparicalcitolorcalcimimetics AT rinconbelloabraham mortalityinhemodialysispatientswithcovid19theeffectofparicalcitolorcalcimimetics AT lopezherradonana mortalityinhemodialysispatientswithcovid19theeffectofparicalcitolorcalcimimetics AT caohigini mortalityinhemodialysispatientswithcovid19theeffectofparicalcitolorcalcimimetics AT hurtadosara mortalityinhemodialysispatientswithcovid19theeffectofparicalcitolorcalcimimetics AT colladosilvia mortalityinhemodialysispatientswithcovid19theeffectofparicalcitolorcalcimimetics AT riberalaura mortalityinhemodialysispatientswithcovid19theeffectofparicalcitolorcalcimimetics AT barbosafrancesc mortalityinhemodialysispatientswithcovid19theeffectofparicalcitolorcalcimimetics AT dapenafabiola mortalityinhemodialysispatientswithcovid19theeffectofparicalcitolorcalcimimetics AT torregrosavicent mortalityinhemodialysispatientswithcovid19theeffectofparicalcitolorcalcimimetics AT brosetajosejesus mortalityinhemodialysispatientswithcovid19theeffectofparicalcitolorcalcimimetics AT sotomontanezcarlos mortalityinhemodialysispatientswithcovid19theeffectofparicalcitolorcalcimimetics AT navarrogonzalezjuanf mortalityinhemodialysispatientswithcovid19theeffectofparicalcitolorcalcimimetics AT ramosrosa mortalityinhemodialysispatientswithcovid19theeffectofparicalcitolorcalcimimetics AT boverjordi mortalityinhemodialysispatientswithcovid19theeffectofparicalcitolorcalcimimetics AT noguessolanxavier mortalityinhemodialysispatientswithcovid19theeffectofparicalcitolorcalcimimetics AT crespomarta mortalityinhemodialysispatientswithcovid19theeffectofparicalcitolorcalcimimetics AT dussoadrianas mortalityinhemodialysispatientswithcovid19theeffectofparicalcitolorcalcimimetics AT pascualjulio mortalityinhemodialysispatientswithcovid19theeffectofparicalcitolorcalcimimetics |